tbuckley/cabot-search huggingface dataset:
Invasive Investigation of the Heart: A Guide to Cardiac Catheterisation and Related Procedures
Authors: Graham Austin Herrock Miller
Journal: Annals of Internal Medicine (1990)

Part 1 Techniques: the catheterization laboratory the tools of catheterization techniques of catheterization - access to the left and right heart techniques of catheterization - catheter manipulation interventional techniques the measurement of pressure and oxygenation angiography quantitative angiocardiography and the assessment of ventricular function respiratory techniques and the measurement of oxygen consumption diagnostic applications of indicator dilution techniques calculations used in cardiac catheterization complications of catheterization. Part 2 Catheterization in specific disorders: coronary arteriography - coronary artery disease coronary angioplasty (PTCA) valvular heart disease myocardial and pericardial disease congenital heart disease congenital heart disease in the adult pulmonary arteriography pulmonary embolism aortography, anomalis of the thoracic aorta management of cardiovascular emergencies in the intensive care unit electrophysiology and pacing - techniques of intracardiac electrophysiology - recording, stimulation and treatment the role of the catheterization laboratory in heart and heart-lung transplantation. Appendices: manufacturers and equipment addresses.
Abstract 16944: Cx43 Hemichannel Inhibition Prevents Arrhythmias in Duchenne Muscular Dystrophy Mice
Authors: J P Gonzalez, Jayalakshmi Ramachandran, Jorge Contreras, Diego Fraidenraich
Journal: Circulation (2014)

Duchenne muscular dystrophy (DMD) is a fatal disease characterized by skeletal and cardiac muscle pathologies due to the absence of the membrane stabilizing protein dystrophin. Although most research has focused on skeletal muscle, 100% of patients over the age of 18 are diagnosed with cardiomyopathy, associated with the development of arrhythmias and eventual heart failure. The connexin proteins, normally responsible for the formation of gap junctions, are known to play a significant role in cardiac conduction. Remodeling of these proteins has been linked to the development of arrhythmias following myocardial infarction. Through analysis of Cx43, the most abundant connexin in the heart, we found that both mild mdx and severe mdx:utr(-/-) models of DMD display significant protein upregulation and mislocalization to the lateral sides of cardiomyocytes. Interestingly, this pattern is more extreme in the severe model, consistent with the degree of cardiac phenotype. To assess the role of Cx43 in DMD arrhythm...
Medical Economics Encyclopedia of Practice and Financial Management.
Authors: Lawrence Farber
Journal: Annals of Internal Medicine (1988)

REVIEWSheterogenous groups of similar seizure behaviors and even the sophistication of modem clinical studies and electroencephalograms does not always coin- cide with the clinical expression of the seizure.Throughout, each author repeatedly emphasizes the absolute need for a careful clinical evaluation, including an accurate history and a step-by-step review of the observed seizure activity followed by a detailed neurological evaluation.In complicated cases, an electroencephalogram can profitably be combined with television monitoring.The chapters contain excellent and concise comparative tables guiding the reader in, for example, the comparative features of absence seizures and complex partial seizures, comparison of jitteriness and seizures in the neonate and risk factors in febrile seizures.These and many other tables are well described in the text.The third subject area covered in the last four chapters describes the treatment of an individual with a seizure disorder, including pharmacologic and surgical management, community support systems and psychosocial considerations.An outstanding chapter by Dr J. Chris Sackellares describes the pharmacologic management.This author provides a general description of drug therapy including toxicity and pharmacokinetics'and then addresses the use of each anticonvulsant drug including indications, dosage, time of administra- tion, levels and interactions among antiepileptic agents.This author and others in the text make a strong plea for specific single drug use and avoidance of "polypharmacology."In the last two chapters, the authors describe community support systems and the impact ofa dramatic disorder upon the lives of a patient and family.This is an excellent book containing information essential to those man- aging seizures in childhood.Though the information is available in the literature, these authors have incorporated an enormous amount of data in this slim volume.In addition, the authors have paid tribute to investigators from the past such as Hughling Jackson, Penfield and Jasper, Gibbs and many others who contributed so much to our current level of understanding, thus providing a nice historical tie between the past and present.Moreover,
An Inventory of Social and Economic Research in Health.
Authors: Frederick R. Strunk
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3761: Diabetic Patients with Abnormal Stress Echocardiography have worse Prognosis Compared to Patients with Known Coronary Artery Disease: A Stress Echocardiography Study
Authors: Sripal Bangalore, Olga Kristof-Kuteyeva, Chris Cianci, Sandeep Joshi, Shruthi Pranesh, Farbod Raiszadeh, Ivan Quintanar-Smith, Deborah Cantales, Siu-Sun Yao, Farooq A Chaudhry
Journal: Circulation (2007)
Health reform law is the "new reality," says Obama
Authors: M. McCarthy
Journal: BMJ (2015)

In an impassioned speech on 9 June defending his signature legislative accomplishment, the US Affordable Care Act, President Barack Obama called the health reform law the “new reality” whose elements have been “woven into the fabric of America.”

“Nobody suggests that somehow our healthcare system is perfect as a consequence of the law being passed, but it is serving so many more people so much better. And we’re not going to go backwards,” Obama said.

Since its …
Accident-and-Health Insurance
Authors: Edwin J Faulkner
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Science in Action: A Sketch of the Value of Scientific Research in American Industries.
Authors: Edward R. Weidlein, William A. Hamor
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic role of interim <sup>18</sup>FDG-PET in Hodgkin lymphoma: A single-center experience
Authors: E. Cocorocchio, A. Vanazzi, E. Botteri, A. Alietti, M. Negri, S. Bassi, L. Preda, L. Travaini, F. A. Peccatori
Journal: Journal of Clinical Oncology (2009)

e19520 Background: The role of FDG-PET for staging and response assessment in Hodgkin lymphoma (HL) is still evolving. We report our experience with the intent of evaluate prognostic role of 18 FDG-PET in terms of long term complete remission (CR). Methods: We retrospectively analysed 65 consecutive pts affected by newly diagnosed HL. Median age was 36 yrs. Histology included 50 classical and 10 lymphocyte predominance HL. According to Hasenclever index, 58 out of 65 pts were considered at low risk, 5 at intermediate and 2 at high risk. 30/65 pts showed good prognosis (defined as IA-IIA, &lt; 3 nodal sites, ERS &lt; 50) and received 4 cycles of VBM followed by involved field (IF) radiotherapy (RT); the remaining 35 pts received hybrid ChlVPP/ABVVP for 6 cycles followed by IF RT in case of bulky disease. All patients underwent 18 FDG-PET scans at diagnosis, after the fourth cycle in the VBM group, after the third cycle in the ChlVPP/ABVVP (interim 18 FDG-PET), at the end of treatment in all patients. Fisher exact test was used to compare percentages between groups. Results: CR was recorded in 60 (92%) pts. Interim 18 FDG-PET was negative in 52 out of 65 pts (80%), all in CR at the end of treatment. Eight out of 13 pts with positive interim 18 FDG-PET obtained a CR at the end of treatment (100% versus 62%, Fisher exact text p&lt;0.01). Six out of 65 pts relapsed: interim 18 FDG-PET was negative in 5 of them, positive in 1 case. Two deaths occurred, one among pts with negative and one with positive interim 18 FDG-PET. After a median follow-up of 30 months, 3-year freedom from treatment failure was 83% and 62% in pts with negative and positive interim 18 FDG-PET, respectively (Log-rank test p&lt;0.01, Hazard Ratio 4.9 (95%CI 1.4–16.1)). Conclusions: In our experience interim 18 FDG-PET demonstrate a predictive role regarding the achievement of CR and treatment failure, at least as relevant as Hasenclever index, but failed to predict clinical result in 12 (18%) pts. Its role in defining the best therapeutical approach in HL pts must be further investigated in randomized clinical trials. No significant financial relationships to disclose.
The Assessment of Area at Risk and Myocardial Salvage After Coronary Revascularization in Acute Myocardial Infarction
Authors: Martin Hadamitzky, Birgit Langhans, Jörg Hausleiter, Carolin Sonne, Adnan Kastrati, Stefan Martinoff, Albert Schömig, Tareq Ibrahim
Journal: JACC. Cardiovascular imaging (2013)
Your weight and how to control it.
Authors: Morris Fishbein
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 15382: p62 Binding to Protein Kinase C ζ Regulates Tumor Necrosis Factor α-Induced Inflammatory and Apoptotic Pathways in Endothelial Cells
Authors: Geun-Young Kim, Patrizia Nigro, Christine K Christie, Amy Mohan, Keigi Fujiwara, Jun-Ichi Abe, Bradford C Berk
Journal: Circulation (2011)

Background: Protein kinase C (PKC)ζ is a key pathological mediator of tumor necrosis factor (TNF)α-induced vascular inflammation. It is the only PKC isoform that is specifically activated in distur...
HER2 amplification through CISH -chromogenic hybridization in situ- on breast cancer Her 2 2+ by immunohistochemistry -ICH
Authors: S. R. Bella, D. Lerda, A. Guidi, R. Theaux, L. Armando, R. Sambuelli
Journal: Journal of Clinical Oncology (2008)

22147 Background: HER 2 gene-localized on chromosome 17 (locus 17 q12–21.32)- is amplified on a 18/20% of breast cancers. It is connected to clinic outcome conceding higher recurrence and mortality rates, predicting resistance to endocrine therapies and chemotherapy without taxanes or anthracyclines and response to anti HER 2 therapies. HER 2 stage may be known by: 1- Putting adjacent the level of membrane proteins -IHQ, ELISA, western blotting or 2- Setting the amplification of the gene through hybridization in situ techniques, PCR or southern blotting. ICH on paraffin fixed tissue with DAKO test identifies tinge patterns like HER 2 - (0 or 1 +) or + (2 and 3 +). Only 15/24% of ICH 2+ tumors are amplified through FISH. Anti HER 2 therapy resulted beneficial only ICH 3+ or amplified patients. CISH uses a DNA HER 2 probe, generated by subtraction technology. In contrast to FISH, it can be visualized using an optic microscope and allows to observe tumor morphology. We describe our experience with CISH to set the amplification of HER2 in samples 2+ by ICH (DAKO) Methods: From March to December 2007, 54 samples of paraffin fixed tissue with ICH interpreted as 2+ for at least two different pathologists, were analyzed by CISH. ICH: carried out using A0485 antibodies (DAKO, dilution 1:100). The result was classified based on tumor cell membrane colouring according to DAKO criterion. CISH was evaluated by Tanner´s criterion: copy numbers 1 to 5 signals per nucleous: unaltered gene, low amplified level: 6 to 10 signals per nucleous in more than 50% of cancerous cells; and high amplified level: more than 10 copies or clusters in more than 50% cancerous cells. CISH, for chromosome 17, has been interpreted as disomy or aneusomy and the copy numbers were compared for HER 2 to define true amplification. Results: 8 (15%) from 54 Her 2 2+ ICH samples presented an amplified gene through CISH Conclusions: 15% of HER2 2+ ICH patients presented gene amplification by CISH Amplified patients had unfavorable characteristics Her 2 Age (years) Metastasis Receptors M1 Nº (%) N Status Nº (%) Amplified 58 Brain 2 Bone 2 Liver 2 E+P+: 2 E-P-:2 4 (50) N-:1 N+: 3 (75) N/amplified 56 Local 6 Bone 4 Lung 4 E+P+:32 E+P-:4 16 (32) N-:14 N+: 16 (53) Cutaneous 2 E-P+:2 E-P-:8 No significant financial relationships to disclose.
Effect of BI 811283, a novel inhibitor of Aurora B kinase, on tumor senescence and apoptosis.
Authors: U. Gürtler, U. Tontsch-Grunt, M. Jarvis, S. K. Zahn, G. Boehmelt, J. Quant, G. R. Adolf, F. Solca
Journal: Journal of Clinical Oncology (2010)

e13632 Background: Aurora B kinase is involved in coordinating multiple steps of mitosis, including chromosome condensation, chromosome segregation and cytokinesis. These essential functions of Aurora B and its over-expression in multiple cancer types render this serine/threonine kinase an attractive target for therapeutic intervention. Methods: Inhibition of cell proliferation was tested in Alamar blue and thymidine incorporation assays. Cell-cycle status was determined by DNA content analysis (FACS, Cellomics). Apoptosis was analyzed by Western blotting for cleaved PARP and assessment of nuclear fragmentation by microscopy of DAPI-stained cells. Senescence was detected by staining for SA-beta-Gal activity. Nude mice were grafted s.c. with non-small cell lung cancer (NSCLC) or colorectal cancer (CRC) tumor cells (cell lines Calu-6 and HCT116, respectively). BI 811283 was administered once weekly to mice bearing established tumors by 24 h s.c. infusion using osmotic mini-pumps. In this schedule, the maximum tolerated dose (MTD) was determined as 20 mg/kg. Results: BI 811283 potently inhibited Aurora B kinase (IC50 = 9 nM) and blocked the proliferation of cells of diverse origin in a panel of 24 cancer cell lines (all EC50 <14 nM). In the four cell lines tested by FACS, the fraction of polyploid cells increased by up to 80% within 48 h, with changes up to 80%. In NCI-H460 cultures, ∼25% of the cells became senescent within 96 h, whereas concomitant hallmarks of apoptosis were only observed in a smaller percentage (7% after 96 h). In nude mouse xenograft models of human NSCLC and CRC, BI 811283 dose-dependently inhibited tumor growth and, at the MTD, tumor regression was observed in a subset of animals. Histological examination of treated tumors showed an accumulation of enlarged, multinucleated cells in accordance with the expected mechanism of action. Conclusions: BI 811283 is a potent Aurora kinase inhibitor that induces mitotic checkpoint override, resulting in nonproliferating, polyploid, and senescent tumor cells. Aurora B inhibition defines a new mechanistic paradigm for M-phase targeting agents. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Boehringer Ingelheim
Abstract 70: Increased Survival After Extracorporeal Membrane Oxygenation Support in Children with Cardiac Disease
Authors: Constantinos Chrysostomou, Victor O Morel, Bradley Kuch, Elizabeth O'Malley, Masahiro Yoshida, Peter Wearden
Journal: Circulation (2011)

Background: In children with cardiac disease ECMO has been used during cardiac arrest unresponsive to conventional CPR (E-CPR), in the cardiac operating room for failure to separate from cardiopulmonary bypass (OR-ECMO) and for low cardiac output syndrome (LCOS-ECMO). Though a life-saving intervention, the so far reported survival after ECMO ranges only from 38-51%. Methods/Results: Records of patients with cardiac disease who received ECMO support between 1/2006 - 12/2010 were evaluated. Measured outcomes included hospital and 28-day survival and transition to ventricular assist device (VAD) or transplant. There were 102 ECMO runs in 98 patients (41 E-CPR, 31 OR-ECMO and 26 LCOS-ECMO). Overall hospital survival was 76% and 28-day survival was 78%. In the E-CPR group more non-survivors (NS) had single ventricle (SV) anatomy, higher surgical complexity, persistent lactatemia and CNS injury. In the OR-ECMO, NS had longer ECMO run and worse ventricular function coming off ECMO. In the LCOS-ECMO, more NS had syndromic features, persistent lactatemia, decreased lung compliance and required plasma exchange (Tables 1, 2). The detailed outcomes of the 3 groups are shown in Table 3. Conclusion: An increased survival after ECMO support was noted in our patient population with cardiac disease. This increased survival was seen in all 3 groups including the E-CPR group where survival was &gt; 75%.
Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
Authors: Heinz Wiendl, Sven G. Meuth
Journal: Drugs (2015)

In individuals with multiple sclerosis, physical and cognitive disability progression are clinical and pathophysiological hallmarks of the disease. Despite shortcomings, particularly in capturing cognitive deficits, the Expanded Disability Status Scale is the assessment of disability progression most widely used in clinical trials. Here, we review treatment effects on disability that have been reported in large clinical trials of disease-modifying treatment, both among patients with relapsing-remitting disease and among those with progressive disease. However, direct comparisons are confounded to some degree by the lack of consistency in assessment of disability progression across trials. Confirmed disability progression (CDP) is a more robust measure when performed over a 6-month than a 3-month interval, and reduction in the risk of 6-month CDP in phase III trials provides good evidence for the beneficial effects on disability of several high-efficacy treatments for relapsing-remitting disease. It is also becoming increasingly clear that therapies effective in relapsing-remitting disease have little impact on the course of progressive disease. Given that the pathophysiological mechanisms, which lead to the long-term accrual of physical and cognitive deficits, are evident at the earliest stages of disease, it remains a matter of debate whether the most effective therapies are administered early enough to afford patients the best long-term outcomes.
Abstract 12846: Impact of CT-Guided Bioprosthesis Sizing on Post-Procedural Aortic Regurgitation in Transcatheter Aortic Valve Implantation
Authors: Kentaro Hayashida, Erik Bouvier, Thierry Lefevre, Thomas Hovasse, Marie-Claude Morice, Bernard Chevalier, Mauro Romano, Philippe Garot, Arnaud Farge, Patrick Donzeau-Gouge, Bertrand Cormier
Journal: Circulation (2011)

Purpose: Measurement of the aortic annulus is crucial for appropriate valve sizing in transcatheter aortic valve implantation (TAVI). The main limitation of transesophageal echography (TEE) is that it measures only the sagital diameter, whereas the aortic annulus has an oval shape. The purpose of this study was to clarify the impact of CT-guided valve sizing on outcomes after TAVI. Method: TAVI was performed in 337 consecutive cases in our institution. TEE-guided valve sizing was conducted in our early experience (n=228). CT-guided approach has been applied since 2010 (n=109). The CT-measured mean annulus diameter was calculated as: mDiam-CT = 2√(annulus surface/π). The outcomes of CT and TEE-guided strategy were compared. Results: The CT group had lower Euroscore (20.6±10.8% vs 24.8±11.5%, p=0.002), higher eGFR (58.6±22.6 vs 49.8±24.2ml/min, p=0.002) and left ventricular ejection fraction (58.6±22.6 vs 49.8±24.2, p=0.002). TEE-measured annulus diameter (Diam-TEE) was similar (22.1±2.0 vs 21.8±1.8mm, p=0....